Clinical readout
Novo links Wegovy to liver and weight gains in real-world MASH studies
Two retrospective analyses tied Wegovy use in adults with MASH to larger drops in liver enzymes, weight and HbA1c. In one, patients lost an adjusted 18.9 lb over six months on Wegovy against 5.6 lb on resmetirom, though resmetirom cut LDL more. Neither study was randomized, so the results cannot show cause and effect.
- Drugsemaglutide
- CompanyNovo Nordisk
- CompanyTexas Liver Institute
- TargetGlucagon-like peptide-1 receptor
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.